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Abstract
A hallmark of malignant gliomas is their ability to disperse through neural tissue, leading to long-term failure of all known
therapies. Identifying new antimigratory targets could reduce glioma recurrence and improve therapeutic efficacy, but
screens based on conventional migration assays are hampered by the limited ability of these assays to reproduce native
cell motility. Here, we have analyzed the motility, gene expression, and sensitivity to migration inhibitors of glioma cells
cultured on scaffolds formed by submicron-sized fibers (nanofibers) mimicking the neural topography. Glioma cells cul-
tured on aligned nanofiber scaffolds reproduced the elongated morphology of cells migrating in white matter tissue and
were highly sensitive to myosin II inhibition but only moderately affected by stress fiber disruption. In contrast, the same
cells displayed a flat morphology and opposite sensitivity to myosin II and actin inhibition when cultured on conventional
tissue culture polystyrene. Gene expression analysis indicated a correlation between migration on aligned nanofibers
and increased STAT3 signaling, a known driver of glioma progression. Accordingly, cell migration out of glioblastoma-
derived neurospheres and tumor explants was reduced by STAT3 inhibitors at subtoxic concentrations. Remarkably,
these inhibitors were ineffective when tested at the same concentrations in a conventional two-dimensional migration
assay. We conclude that migration of glioma cells is regulated by topographical cues that affect cell adhesion and gene
expression. Cell migration analysis using nanofiber scaffolds could be used to reproduce native mechanisms of migration
and to identify antimigratory strategies not disclosed by other in vitro models.
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Introduction
Cell migration away from the site of the primary tumor is a hallmark
of malignant cancers often leading to recurrence and the failure of
existing therapies. This is particularly evident in malignant gliomas,
the most challenging tumor of the central nervous system character-
ized by its ability to disperse through normal neural tissue and recur
after initial treatment [1].
Histologic evidence has shown that glioma cell dispersion in the
brain occurs along preferential patterns, in many cases following the
orientation of thin, elongated anatomic structures such as capillaries,
white matter fibers, and unmyelinated axons [2]. Unfortunately, stan-
dard assays devised to study glioma cell motility do not incorporate
such topographical cues guiding cell adhesion and traction in vivo,
focusing instead on cell motility on either rigid (i.e., polystyrene or
glass) surfaces or invasion through a homogeneous, collagen-based
matrix that is absent in neural tissue [3,4].
Motile glioma cells are more resistant than nonmotile cells to
apoptotic stimuli [5,6], and current evidence suggests that conven-
tional therapies may in fact trigger glioma cell dispersion [7,8]. Thus,
understanding the mechanisms of glioma cell migration is critical to
the development of more efficient targeting strategies as part of adju-
vant therapy. Antimigratory approaches against gliomas have targeted
cell adhesion molecules or tumor-associated proteases, following anti-
metastatic strategies used in other solid tumors [9]. However, these
approaches have been largely ineffective in the clinical setting, partly
because of the ability of brain tumor cells to shift between different
mechanisms of cell adhesion as well as proteolytic and nonproteolytic
modes of migration [3,10]. This underscores the need for additional
studies to identify antimigratory compounds capable of targeting the
master regulators of tumor cell locomotion [3].
In a recent study, we demonstrated that glioma cells can be
cultured on scaffolds made of poly-ɛ-caprolactone nanofibers pro-
duced by electrospinning [11]. Fiber density, alignment, and stiff-
ness can be controlled in these scaffolds, thus providing the cells
with a topographically complex substrate. Glioma cells were able
to grow on nanofibers of different alignment and accurately repro-
duced the morphologies described for these cells migrating through
neural tissue [10,12]. Here, we show that migration of glioma cells
on nanofiber scaffolds reproduces not only the morphology but also
characteristic molecular features of three-dimensional migration
and results in a pattern of gene expression dependent on fiber align-
ment. Moreover, we show that active cell migration on aligned nano-
fibers correlates with activation of the transcription factor STAT3,
a central regulator of tumor progression and metastasis in solid
cancers [13]. Accordingly, subtoxic inhibition of STAT3 specifically
reduced glioma cell migration on nanofibers, suggesting that this
novel culture technology could be used for screening of antimi-
gratory compounds.
Materials and Methods
Preparation of Nanofiber-Coated Culture Plates
Poly-ɛ-caprolactone nanofibers were prepared as previously de-
scribed [11] with minimal modifications. Briefly, optically clear poly-
styrene film (thickness, 190 μm; MultiPlastics, Inc, Lewis Center, OH)
was cut to the desired final size and attached to the side of a rotating drum
(Nanofiber Solutions, Columbus, OH). Nanofibers were deposited by
electrospinning, using a syringe perpendicular to the polystyrene film as
described [11]. Fiber alignment was controlled by the rotational speed
of the drum and scaffold thickness by the amount of time used to de-
posit the nanofibers. Films covered with multilayered nanofiber scaffolds
were trimmed, attached to bottomless culture plates (Figure 1A), and
sterilized with UV radiation (350 mJ/cm2) before use.
Cell Cultures and Reagents
The human glioma cell lines U87 and U251 (American Type
Culture Collection, Manassas, VA) were grown at 5% CO2 in Dulbecco
modified Eagle medium supplemented with 10% fetal calf serum. The
identity of these cells was confirmed through “Cell Check” authentica-
tion service provided by the Research Animal Diagnostic Laboratory
(Columbia, MO). Two cultures of glioblastoma-derived tumor initiat-
ing cells (G8 and G9) were prepared from freshly resected tumors and
cultured as neurospheres in serum-free medium as described [14].
These cells have been characterized as tumor stem cells elsewhere [15],
display self-renewal in vitro, and are highly tumorigenic in vivo, repli-
cating the phenotype of the original tumors. Only low passages of G8
and G9 cells (up to five passages) were used.
To prepare tumor xenografts, G8 and G9 cells were implanted in
the striatum of athymic mice as described [16]. After 2 weeks, ani-
mals were perfused with saline, and tumors were resected and minced
in Hank’s balanced salt solution. Tissue explants were cultured in
suspension in neurosphere medium for 72 hours, with daily changes
of medium to remove debris. Explants containing viable tumor cells
were detected by uptake of the fluorescent dye calcein-AM (5 μM;
Invitrogen, Carlsbad, CA) and deposited on nanofiber scaffolds. As an
alternative strategy, cells were first stably transduced with the lentiviral
vector pCDH-EF1-coGFP (System Biosciences, Mountain View, CA)
and used to generate tumors as above. Tissue pieces containing GFP-
expressing tumor were processed under a fluorescence dissection micro-
scope, cleaned of debris in Hank’s balanced salt solution, and deposited
on nanofiber scaffolds. Patterns of cell migration out of tissue explants
were undistinguishable using either approach.
To inhibit cell migration, glioma cells were treated with the
myosin II inhibitor blebbistatin (Sigma-Aldrich, St Louis, MO) and
the actin polymerization inhibitor cytochalasin D (Sigma-Aldrich).
To test the involvement of STAT3 on migration, cells were treated with
the STAT3 inhibitors stattic (Tocris Bioscience, Ellisville, MO) [17]
and LLL12 (Division of Medicinal Chemistry, Ohio State University,
Columbus, OH) [18]. Cell viability was determined using an assay for
reduction of soluble tetrazolium (CellTiter kit; Promega, Madison, WI).
Adhesion and Migration Assays
To quantify cell adhesion to nanofibers, glioma cells were dissoci-
ated and plated (30,000 cells/200 μl) in triplicate on nanofiber-coated
or tissue culture polystyrene (TCPS) plates. After 30 minutes at 37°C,
cells were washed, fixed, and quantified as described [19].
To analyze cell migration on nanofibers, 50,000 to 75,000 glioma
cells were plated on 35-mm agar plates to form spheroids [16]. After
48 hours, glioma spheroids 200 to 250 μm in diameter were stained with
5 μM CellTracker CMFDA (Invitrogen) and manually placed within
nanofiber-coated wells. To analyze the migration of glioblastoma-derived
initiating cells, either from neurospheres or from tumor explants, nano-
fibers were first precoated with 5 μg/ml fibronectin in phosphate-
buffered saline for 2 hours. Migration index was calculated as the ratio
of maximum dispersion (Figure W1A) divided by the original diameter
of the spheroids.
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To analyze cell migration on TCPS plates, glioma cells were tested
using conventional wound healing and radial dispersion assays as
previously described [20]. To analyze cell translocation (“Transwell
assay”), 30,000 cells were applied to uncoated cell culture inserts with
8-μm pores (Greiner Bio-One, Monroe, NC). Migration in response
to a chemoattractant gradient (0%-10% serum) was measured after
8 hours by counting the number of transmigrated cells.
To analyze cell migration using an organotypic culture model, cul-
tures of mouse neonatal brain slices were prepared as we have previ-
ously described [16]. Aggregates of GFP-expressing glioma cells were
pretreated overnight with STAT3 inhibitors, deposited on the tissue
slices, and followed by fluorescence microscopy for up to 96 hours.
Dispersion was quantified by analyzing the total area and perimeter
covered by the migratory cells [16].
Figure 1. Glioma cell morphology and migration are directed by substrate topography. (A) Representative photography of a multiwell
culture plate with a nanofiber-coated backing film. The enlarged image shows the translucent coating of nanofibers, and the double-
headed arrow indicates the direction of fiber alignment. (B) Scanning electron microscope images of randomly oriented and highly
aligned nanofibers. Bars, 5 μm. (C-E) Images of calcein-stained U251 glioma cells cultured on highly aligned nanofibers (C), randomly
oriented nanofibers (D), or conventional TCPS (E). Bars, 100 μm. (F) Quantification of cell adhesion (U251 cells/mm2) showed significantly
lower adhesion of cells to nanofibers compared with TCPS (***P < .001), but no differences between randomly oriented and aligned
nanofibers (analysis by one-way ANOVA and Bonferroni post hoc tests). (G) Radial dispersion of U251 cells from cell aggregates was
measured using nanofiber scaffolds of different thickness. Cells gained motility much faster on aligned than on randomly oriented nano-
fibers as the fibers became sparser. Use of 70-μm-thick scaffolds (dashed line) resulted in the highest cell motility on aligned nanofibers but
little motility of the same cells on randomly oriented nanofibers.
Neoplasia Vol. 13, No. 9, 2011 Glioma Cell Migration on Nanofibers Is STAT3-Dependent Agudelo-Garcia et al. 833
All experiments of cell migration were performed three times with
at least three independent replicates per condition except brain slice
experiments, which used eight replicates.
Microarray Experiments
To compare gene expression of glioma cells migrating on aligned
versus randomly oriented nanofibers 5 × 105 U251 cells were cultured
in nanofiber-coated 60-mm culture plates, collected after 48 hours, and
processed with TRIzol (Invitrogen) according to standard protocols.
Total RNA from independent triplicates was processed for hybridiza-
tion to Affymetrix U133+ 2.0 microarrays at The Ohio State University
Microarray Shared Resource. Data were deposited in the National
Center for Biotechnology Information’s Gene Expression Omnibus
Repository for Functional Genomic Studies (data set GSE28167). Sig-
nificantly upregulated genes (>1.5-fold; Table W1) in cells cultured on
aligned nanofibers were analyzed using Ingenuity Pathway Analysis to
identify top functional networks and DAVID bioinformatics resources
to identify top functional clusters (Table W2). Quantitative reverse
transcription–polymerase chain reaction (RT-PCR) was performed in
parallel samples to verify the expression level of selected messenger
RNA (primers listed in Table W3).
Western Blot Analysis
Dissociated U251 and G9 cells cultured in nanofiber-coated 60-mm
culture plates were lysed in situ in 20 mM Tris-HCl buffer, pH 7.6,
containing 150 mM NaCl, 1% vol/vol NP-40, 0.5% vol/vol sodium
deoxycholate, and protease plus phosphatase inhibitors (Complete
and PhosSTOP cocktails; Roche Applied Science, Indianapolis, IN).
Proteins were processed for Western blot analysis with antibodies
against STAT3 and phospho-Tyr705 STAT3 (Cell Signaling Technology,
Danvers, MA), myosin light chain 2 (MLC2) and phospho-Ser19
MLC2 (Cell Signaling), and β-tubulin (Sigma-Aldrich).
Statistical Analysis
Cell adhesion and translocation experiments were analyzed by one-
way analysis of variance (ANOVA) followed by post hoc Bonferroni
tests. Cell migration on nanofibers, TCPS, or brain slices was analyzed
by two-way ANOVA for repeated measures. Results of STAT3 in-
hibition on nanofibers were analyzed by one-way ANOVA for each
inhibitor and cell type. P < .05 indicates significant differences be-
tween treatments. Bar graphs in the figures represent mean ± SD.
Microarray data were analyzed by robust multichip average procedure
using quantile normalization. Differentially expressed genes between
two groups were identified with a modified t test [21] using BRB-Array
Tools software.
Results
Glioma Cell Morphology and Migration Depend
on Fiber Alignment
To better understand the mechanisms underlying glioma cell
migration in response to variable topographical cues, we first analyzed
the morphology and behavior of glioma cells cultured on three-
dimensional nanofiber scaffolds versus conventional two-dimensional
surfaces. Dissociated U251 glioblastoma cells were plated on conven-
tional TCPS plates and compared against cells cultured on two dis-
tinct types of nanofiber scaffolds (50 μm thick; Figure 1, A and B).
Cells cultured on aligned nanofibers adopted a fusiform morphology,
usually with a leading process following an individual fiber (Figure 1C).
In contrast, cells on randomly oriented fibers remained relatively
rounded (Figure 1D). In neither case did we see obvious lamellipodia
or fan-shaped morphologies that were typical of these cells cultured on
TCPS (Figure 1E ). Despite their different morphologies, initial cell
adhesion was similar on both types of nanofiber substrates, although
considerably lower than adhesion to TCPS (Figure 1F ).
Next, we quantified cell migration on nanofibers using a radial
migration assay to measure cell dispersion out of a tumor aggregate
or “core” [11,20] (Figure W1A). Glioma cell spheroids were plated
on nanofiber scaffolds of different thickness (10-200 μm) to determine
the effect of fiber density on cell migration. We observed that cell
migration was very restricted at the highest fiber densities and, as
expected, increased as the nanofibers became sparser (Figures 1G and
W1B). Interestingly, migration on highly aligned nanofibers peaked on
relatively thick scaffolds (60-80 μm), whereas migration on randomly
oriented nanofibers remained low until the fibers were very sparse
(<30 μm thick), which likely allowed the cells to contact the underlying
substrate [11]. Therefore, we chose 70-μm-thick nanofiber scaffolds for
our subsequent experiments to provide maximum differences in total
cell motility between the two different types of fiber orientations.
Glioma Cell Migration on Aligned Nanofibers
Is Myosin II Dependent
Recent work has shown that cell motility in a three-dimensional
environment is a substantially different process from migration on rigid
two-dimensional surfaces, being less dependent on focal adhesions and
long, anchored, stress fibers and more on the local contraction of
actomyosin complexes to squeeze the tail-end of the cell through inter-
cellular spaces [10,22]. To determine whether migration of glioma cells
on nanofiber scaffolds reproduced this key molecular feature of three-
dimensional migration, we assessed the effect of inhibitors targeting
myosin II and actin polymerization on cell migration.
Migration of U251 glioma cells out of aggregates seeded on
aligned nanofibers was significantly inhibited by the myosin II inhib-
itor blebbistatin (Figure 2, A and B). However, blebbistatin did not
affect glioma cells on randomly oriented nanofibers, where motility was
already restricted. When we compared these results with a conventional
cell translocation assay where the cell body must be squeezed through
the pores of culture inserts, we observed that blebbistatin partially
inhibited the translocation of glioma cells but at a considerably higher
concentration than that needed to inhibit cell migration on nanofibers
(Figure 2C ). In contrast, in a conventional wound healing assay
(Figure 2D), glioma cell migration was not affected by blebbistatin,
in agreement with the literature [10]. Overall, these results suggested
that cell motility on aligned nanofibers was highly dependent on
myosin II activity as in other three-dimensional models.
On the other hand, the inhibitor of actin polymerization cyto-
chalasin D was much less effective in inhibiting cell motility on
nanofibers compared with the same cells plated on TCPS. Cytochalasin
D treatment of U251 cells caused some disruption of cortical F-actin,
visualized as appearance of punctuate actin staining (Figures 3A and
W2). However, cell dispersion on aligned nanofibers was only reduced
significantly (P < .01) when U251 cells were exposed to toxic concen-
trations of this inhibitor (>2 μM). In comparison, dispersion of the
same glioma cells on TCPS, measured with a radial migration assay
(Figure 3B) or a wound healing assay (Figure W2), was significantly
reduced (P < .001) at the lowest concentration of cytochalasin D tested
(0.2 μM), and cells not only stopped migrating but also detached from
the plates at a 2-μM concentration of this inhibitor. These results
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suggested that, while actin polymerization was still required for cell
migration on nanofibers, the formation of long stress fibers was less crit-
ical than for motility of a rigid surface [23]. Together, the results from
acto–myosin II disruption suggested that cell migration on nanofibers
reproduced more closely the molecular features observed on three-
dimensional migration rather than those observed for migration on
rigid two-dimensional surfaces.
Cell Migration on Aligned Nanofibers Results in Elevated
JAK/STAT Signature
Both here and in a previous study [11], we have observed a sub-
stantial difference in the behavior of glioma cells cultured on aligned
nanofibers, where the cells migrate efficiently, versus randomly oriented
nanofibers, where migration is highly restricted without evident effects
on viability. Therefore, we investigated whether the different migratory
behavior of glioma cells that were otherwise equivalent for viability [11]
or adhesion (Figure 1F ) was reflected in differential gene expression.
Using microarray analysis to compare U251 glioma cells cultured
on aligned versus randomly oriented nanofibers, we observed signif-
icant differences in gene expression (summarized in Table W1).
Pathway and gene ontology analysis suggested a strong association
between the genes upregulated in cells cultured on aligned nanofibers
and functional clusters involved in positive regulation of cell motility
(Table W2). Strikingly, there was a remarkable up-regulation of genes
that are known activators or targets of JAK/STAT signaling [24–26],
including IL8, IL11, TLP, CXCL2, CCND1, PIK3CD, SPHK1,
PIK3CD, and SERPINE1. Up-regulation of these genes in cells cul-
tured on aligned nanofibers was subsequently validated by quantitative
RT-PCR (Figure 4A).
Because these results suggested a possible involvement of STAT
signaling in glioma cell migration, we focused on the transcription
factor STAT3, which has been recently highlighted as a central reg-
ulator of malignant progression in high-grade gliomas [27]. In
agreement with our results of gene expression, Western blot analy-
sis results showed that the active phosphorylated form of STAT3
was markedly increased in cells cultured on aligned nanofibers
shortly after the cells attached to the substrate, whereas it was
barely detectable in cells on randomly oriented nanofibers, even after
Figure 2. Glioma cell migration on aligned nanofibers is myosin II–dependent. (A) Representative images of U251 glioma cell aggregates
after being cultured for 24 hours on aligned or randomly oriented nanofibers, in the presence of 10 μM blebbistatin (blebbistatin) or its
vehicle (control). Notice the parallel and elongated migration profile of cells on aligned nanofibers. Dashed outlines indicate the size and
shape of the same aggregates at t = 0 h. Bars, 200 μm. (B) Effect of blebbistatin on cell dispersion on nanofibers. Results indicate a
significant inhibition of cell migration on aligned but not on randomly oriented nanofibers. ***P < .001 by two-way ANOVA. (C) Effect of
blebbistatin on cell translocation through cell culture inserts. Results indicate a significant effect only at 25 μM blebbistatin. *P < .05 by
one-way ANOVA and Bonferroni post hoc test. (D) Effect of blebbistatin on two-dimensional cell migration measured with a wound
healing assay. Migration of U251 cells in this assay was not affected by the myosin II inhibitor.
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24 hours in culture (Figure 4B). In agreement with previous literature
[28–30], active phosphorylated STAT3 was also highly expressed in
glioma cells cultured on TCPS, where cell motility is unimpeded by
the substrate.
Inhibition of STAT3 Reduces the Migration of Glioma Cells
on Nanofiber Scaffolds
To determine whether cell migration on nanofibers could be used as
a model to analyze the role of STAT3 on glioma cell migration, we
tested two STAT3 inhibitors that specifically prevent STAT3 phos-
phorylation of Tyr705, a critical residue necessary for STAT3 dimeriza-
tion and transcriptional activity. Both inhibitors, stattic and LLL12,
significantly inhibited the migration of U251 cells cultured on aligned
nanofibers (Figures 5, A and B, andW3), at concentrations (0.5-2.0 μM)
that did not affect cell viability during these short assays (Figure W4).
These results were reproduced with an additional glioma cell line
(U87) and two preparations of primary glioblastoma-derived initiating
cells (G8 and G9); all of them tested on aligned nanofibers. Moreover,
the inhibition of cell migration matched the reduction or complete in-
hibition of STAT3 phosphorylation by these compounds (Figure 5, C
and D).
Interestingly, these subtoxic concentrations of stattic or LLL12 were
unable to inhibit cell motility when tested in a conventional wound
healing assay (Figure 5E), suggesting that the inhibitors had disrupted
a sensitive mechanism necessary for cell migration in three-dimensional
nanofiber scaffolds but not on rigid two-dimensional surfaces. In agree-
ment, the phosphorylation of STAT3 andMLC2, a regulatory chain of
myosin II necessary for myosin activity, were significantly reduced in
cells treated with a low concentration of stattic on aligned nanofibers
but not on polystyrene dishes (Figure W5). Together with our results
showing that myosin II activity was critical for cell migration on aligned
nanofibers (Figure 2), these results suggested that actomyosin activity
on nanofibers, but not on TCPS, was finely regulated by STAT3 and
highly sensitive to partial STAT3 inhibition. The sensitivity of glioma
cell migration to low concentrations of STAT3 inhibitors was also
observed in cells dispersing in cultured brain slices, a complex three-
dimensional environment reproducing the natural cytoarchitecture
and natural barriers to cell movement in the brain (Figure W6), sug-
gesting that cell migration on nanofibers was supported by similar or
the same mechanisms as in complex three-dimensional organotypic cul-
tures. In contrast, inhibition of STAT3 did not reduce cell translocation
in a Transwell migration assay at low concentrations of inhibitors (not
shown) and had only a partial effect at high concentrations (LLL12 >
10 μM) that likely affected cell viability to some extent [18].
Because culture of tumor-derived neurospheres on nanofiber scaf-
folds required minimal processing steps and was highly reproducible,
we finally asked if this culture model could be used to analyze cell mi-
gration directly out of fresh, biopsy-like tissue explants. We generated
intracranial tumor xenografts using primary glioblastoma cells and re-
covered the tumors as well as adjacent brain tissue after 2 weeks. Viable
tumor pieces, identified by calcein uptake or GFP fluorescence as indi-
cated in the methods section, were minced, cleared of debris, and plated
on fibronectin-coated aligned nanofibers. Cell migration took longer to
be detected than migration out of homogeneous tumor neurospheres,
but there was consistent glioma cell migration out of the tissue explants
and along aligned nanofibers within 48 to 72 hours (Figure 6A). More
importantly, treatment of the tumor explants with the two STAT3
inhibitors reduced significantly or abolished the outward migration of
glioma cells (Figure 6B).
Taken together, our results revealed a possible role for STAT3 in
the migration of glioma cells in response to topographical cues and
demonstrated the advantages of three-dimensional nanofiber scaf-
folds as a culture model to investigate pathways involved in cancer
cell migration.
Figure 3. Cell migration on nanofibers is less sensitive to stress
fiber disruption than two-dimensional migration. (A) U251 glioma
cell aggregates were cultured on aligned nanofibers, fixed after
24 hours, and stained with phalloidin–Alexa 594 to label actin F.
Results show diffuse cortical staining in vehicle-treated cells (vehi-
cle) versus punctuate staining (insets) along actin filaments in
cells treated with the actin polymerization inhibitor cytochalasin D
(cyt-D, 2 μM). Cell morphology was little or not affected in these
conditions. Bars, 100 μm. (B) Quantification of radial dispersion
of U251 cells shows that two-dimensional cell dispersion on
TCPS was significantly reduced even at the lowest concentration
of cytochalasin D tested (0.2 μM), whereas dispersion on nano-
fibers required 10 to 100× higher concentrations to be signifi-
cantly inhibited. **P < .01, ***P < .001 by one-way ANOVA for
each treatment.
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Discussion
Malignant gliomas have a very poor prognosis owing to their extensive
infiltration of the surrounding normal neural tissue [2]. This infiltra-
tion is triggered in part by chemotherapy and radiotherapy [7,8,31],
and motile glioma cells are highly resistant to these treatments [5,32].
Thus, understanding the mechanisms that drive glioma cell motility
may improve not only the development of anti-invasive strategies but
also the efficacy of current adjuvant therapies.
In this context, a major problem in studying cell motility in vitro is
the difficulty of reproducing the native behavior of these tumor cells.
With few exceptions [9], assays to study glioma cell invasion have largely
reproduced the models used to study motility of other epithelial solid
tumors, such as the wound healing assay (two-dimensional motility)
and invasion through collagen-based matrices (three-dimensional
motility) [9]. Glioma cells in these assays are exposed to a uniform
environment—either an infinite flat surface or a uniform matrix—that
lacks directional mechanical cues relevant to native mechanisms of cell
migration in the brain. In response to limitations of other models, we
developed a topographically complex environment for cell culture,
using biocompatible scaffolds formed by electrospun submicron-sized
fibers [11]. These scaffolds have mechanical properties, such as a low-tensile
modulus (∼7 MPa), comparable with those of biologic tissues [33] and
are therefore highly compliant compared with tissue culture polystyrene
(tensile modulus∼3600MPa). This has allowed us to challenge glioma
cells with a deformable substrate containing variable topography and
analyze the molecular mechanisms involved in cell migration under
these conditions.
Glioma cells adhered to nanofibers with less efficiency than to
conventional TCPS, possibly due to less resistance from the substrate
for the formation of focal adhesions [34,35], but total adhesion was
independent of substrate topography (Figure 1F ). In contrast, the
actual migration of the cells was tightly dependent on the properties
of the substrate, including both nanofiber alignment and density.
Although the cells were not embedded in a matrix, we have previously
shown that they can crawl through or become entangled in several
layers of fibers [11]. The substrate is therefore irregular enough for
the cells to exhibit three-dimensional migratory patterns, such as
the marked body alignment and formation of protrusions along fibers,
mimicking the formation of protrusions through the pores of a matrix
and the elongated appearance of glioma cells migrating in vivo
[10,36]. Furthermore, our data suggest that cell motility in nanofibers
reproduced, at least in part, molecular features of three-dimensional
Figure 4. Glioma cell migration on aligned nanofibers correlates with activation of STAT3 signaling. (A) Quantitative RT-PCR results
showing differential gene expression levels in glioma cells cultured on aligned versus randomly oriented nanofibers (selected genes
are a subset of those listed in Table W1). Many of the upregulated genes are known modulators or targets of JAK/STAT and are involved
in positive regulation of cell migration (Table W2). (B) Dissociated U251 glioma cells (5 × 105 cells/ml) were plated on aligned (A) or
randomly oriented (R) nanofibers and collected 6 or 24 hours after attachment. Cells recovered from aligned nanofibers showed a sub-
stantial increase in Y705-phosphorylated STAT3 (p-STAT3) compared with cells recovered from randomly oriented nanofibers. As a con-
trol, U251 cells were plated on conventional TCPS and processed in the same manner, showing considerable expression of total and
active STAT3 at all times tested.
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motility such as stringent myosin II dependence [10] and low sensitiv-
ity to disruption of stress fibers [23], which contrasted with the oppo-
site features of the cells cultured on rigid two-dimensional surfaces.
Using an optimal combination of nanofiber density and alignment
to promote (aligned nanofibers) or restrict (random nanofibers) cell
dispersion, we demonstrated a substantial up-regulation of STAT3
signaling in migratory glioma cells on nanofibers. The transcription
factor STAT3 is a key regulator of development and metastasis in
solid tumors [13,37] and has been recently proposed as a major driver
of glioblastoma progression [27]. STAT3 promotes glioma stem cell
proliferation and pluripotency [38] and drives tumor development
toward an aggressive mesenchymal phenotype [27], therefore being a
target with significant clinical potential [39]. Indeed, down-regulation
of STAT3 efficiently reduces glioma cell proliferation, induces apoptosis,
and inhibits tumor growth in vivo [40–42]. This has prompted the
recent development of novel small-molecule therapeutic agents target-
ing STAT3 in brain tumors [43,44].
Because the down-regulation of STAT3 in gliomas causes rapid cell
death in vitro, the role of this transcription factor in glioma cell migra-
tion has not been extensively explored. de la Iglesia et al. [45] have
reported that overexpression of constitutively activated STAT3 reduced
glioma cell migration, possibly due to repression of interleukin 8 (IL-8)
signaling. However, because STAT3 is known to activate IL-8 expres-
sion in other cell models [46,47] and is in turn regulated by IL-8 and
other cytokines [48], this paradoxical effect of STAT3 could have been
caused by an overexpressed construct lacking regulatory feedback in
transfected cells. In contrast, recent studies have suggested that inhibi-
tion of STAT3 reduces glioma cell migration [18,30,49], although that
effect was achieved in most cases using conditions that induced cell
apoptosis at the same time.
Figure 5. STAT3 inhibition reduces glioma cell migration on aligned nanofibers. (A and B) Cell dispersion was measured for two glioma
cell lines (U251 and U87) and neurospheres from two glioblastoma-derived initiating cells (G8 and G9), in the presence of the STAT3
inhibitors stattic (A) and LLL12 (B). Both inhibitors significantly reduced cell migration at concentrations between 0.5 and 2 μM. *P< .05,
**P < .01, ***P < .001 by one-way ANOVA for each cell type and inhibitor. (C and D) Western blot analysis of U251 and G9 cells
collected from aligned nanofibers confirmed the inhibition of STAT3 phosphorylation (pSTAT3) using LLL12 (C) and stattic (D) at the
same concentrations used to inhibit cell dispersion. STAT3 inhibition in G9 cells—which form large compact tumorspheres—was some-
times incomplete at low concentrations of LLL12 or stattic, but cell motility was, nevertheless, reduced. Complete STAT3 inhibition was
achieved at higher concentrations of these inhibitors. (E) Migration of U251 cells using a wound healing assay was not affected by low
concentrations of STAT3 inhibitors. NS indicates nonsignificant.
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An important finding of our study is the observation that cell motil-
ity in nanofiber scaffolds was STAT3-dependent and could be specifi-
cally disrupted with low, subtoxic concentrations of STAT3 inhibitors.
This effect was reproduced with glioma cells dispersing in cultured
brain slices, suggesting that migration through both types of topograph-
ically complex environments was supported by similar molecular
mechanisms. Remarkably, low concentrations of STAT3 inhibitors
did not affect cell motility on two-dimensional surfaces. A possible
explanation for these results is that STAT3 could regulate molecular
mechanisms leading to actomyosin activity in glioma cells, which is crit-
ical for three-dimensional motility but can be compensated by alterna-
tive mechanisms in two-dimensional motility [10,23]. Accordingly,
low concentrations of a STAT3 inhibitor reduced the activation of a
myosin regulatory chain (MLC2) only in cells cultured on nanofibers,
which could explain the significant effect of partial STAT3 inhibition
on three-dimensional motility and lack of effect on two-dimensional
motility. In agreement, STAT3 has been implicated as a mediator of
Rho GTPase signaling [50], which is critical for actomyosin contraction
and tail-end retraction necessary for glioma cell movement in three-
dimensional matrices [51]. Interestingly, the expression of proinvasive
metalloproteases that are STAT3 targets, such as MMP2 and MMP9
[30], did not change after STAT3 inhibition on nanofibers (not
shown), suggesting that the role of STAT3 was specific to regulating
motility rather than invasive mechanisms in a three-dimensional con-
text. Overall, our results show that partial inhibition of STAT3 phos-
phorylation is sufficient to reduce glioma cell migration, underscoring
the potential of this transcription factor as a novel target for combined
anti-invasive and cytotoxic strategies in gliomas.
Although we have used the nanofiber scaffolds as a novel culture
model for glioma cells, it should be possible to extend these studies
to other tumor cell types that disperse in vivo along anatomic structures,
such as pancreatic, prostate, or head and neck tumors that use perineural
migration for metastasis [52]. In all these cases, the topographically
complex nature of nanofiber scaffolds could provide considerable ad-
vantages over other models to study three-dimensional cell migration.
Whereas organotypic models (i.e., tissue slices) represent a more accu-
rate mimicry of the microenvironment, challenging cells to migrate and
invade in a manner consistent with their behavior in vivo [53], nano-
fiber scaffolds offer several practical advantages such as a simpler setup,
scaling-up capability, and easy cell recovery for downstream analysis. In
addition, our results suggest that, for glioma cells, migration in nano-
fibers and brain slices is comparable and highly sensitive to subtoxic
doses of antimigratory compounds that may lack effect on rigid two-
dimensional surfaces or may require much higher concentrations to
elicit a comparable effect.
Finally, the possibility of measuring cell migration out of tissue
explants suggests that this model could potentially be used as a bio-
assay for drug testing in specimens and tumorspheres derived from
individual patients.
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Figure W1. Analysis of cell migration on nanofiber scaffolds. (A) Images captured by fluorescence microscopy were analyzed using
ImageJ software to quantify cell dispersion from the original spheroid. The maximum dispersion distance is the Feret diameter of
the whole cell population at each time point. (B) Representative image of U251 glioma cells dispersing out of aggregates cultured
on nanofiber scaffolds of different thickness (30-150 μm). Notice the elongated profile of cell dispersion on highly aligned nanofibers.
Bars, 200 μm.
Table W1. Gene Up-regulation in Glioma Cells Migrating on Aligned Nanofibers.
Gene Symbol Entrez Gene Name Location Type(s) Fold Change P
IL8 Interleukin 8 Extracellular space Cytokine 3.450 2.38e − 03
KLF2 Kruppel-like factor 2 (lung) Nucleus Transcription regulator 3.080 2.98e − 03
CTH Cystathionase (cystathionine gamma-lyase) Cytoplasm Enzyme 2.780 8.53e − 03
BTBD11 BTB (POZ) domain containing 11 Nucleus Transcription regulator 2.610 4.59e − 04
TSLP Thymic stromal lymphopoietin Extracellular space Cytokine 2.490 9.96e − 03
CBS Cystathionine-β-synthase Cytoplasm Enzyme 2.450 6.64e − 03
TMEM158 Transmembrane protein 158 (gene/pseudogene) Plasma membrane Other 2.410 1.49e − 03
SPHK1 Sphingosine kinase 1 Cytoplasm Kinase 2.370 4.99e − 03
MGLL Monoglyceride lipase Plasma membrane Enzyme 2.340 4.76e − 03
NT5E 5′-Nucleotidase, ecto (CD73) Plasma membrane Phosphatase 2.330 1.03e − 03
ASNS Asparagine synthetase (glutamine-hydrolyzing) Cytoplasm Enzyme 2.300 5.85e − 03
CXCL3 Chemokine (C-X-C motif ) ligand 3 Extracellular space Cytokine 2.250 4.44e − 04
PPP1R15A Protein phosphatase 1, regulatory (inhibitor) subunit 15A Cytoplasm Other 2.210 7.16e − 03
CD55 CD55 molecule, decay accelerating factor for complement Plasma membrane Other 2.140 7.77e − 03
TRIB3 Tribbles homolog 3 (Drosophila) Nucleus Kinase 2.030 7.96e − 03
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 Cytoplasm Enzyme 2.020 2.27e − 03
NAV3 Neuron navigator 3 Unknown Other 1.990 8.22e − 04
CAMK2N1 Calcium/calmodulin–dependent protein kinase II inhibitor 1 Plasma membrane Kinase 1.970 1.77e − 03
PSAT1 Phosphoserine aminotransferase 1 Cytoplasm Enzyme 1.940 4.10e − 03
DUSP5 Dual-specificity phosphatase 5 Nucleus Phosphatase 1.930 2.05e − 03
HBEGF Heparin-binding EGF-like growth factor Extracellular space growth factor 1.920 2.89e − 03
RGMB RGM domain family, member B Plasma membrane Other 1.900 2.42e − 04
CXCL2 Chemokine (C-X-C motif) ligand 2 Extracellular space Cytokine 1.890 1.29e − 03
ADAMTS6 ADAM metallopeptidase with thrombospondine type 1 motif, 6 Extracellular space Peptidase 1.840 5.77e − 03
HMGA2 High-mobility group AT-hook 2 Nucleus Other 1.840 1.64e − 03
EDG1 Sphingosine-1-phosphate receptor 1 Plasma membrane G protein–coupled receptor 1.820 3.25e − 04
MICAL2 Microtubule-associated monoxygenase, calponin and LIM domain containing 2 Cytoplasm Other 1.800 1.18e − 03
CCND1 Cyclin D1 Nucleus Other 1.780 6.51e − 03
EPHB2 EPH receptor B2 Plasma membrane Kinase 1.780 1.01e − 03
SERPINE1 Serpine peptidase inhibitor, clade E, member 1 Extracellular space Other 1.770 8.82e − 03
DDR2 Discoidin domain receptor tyrosine kinase 2 Plasma membrane Kinase 1.720 3.38e − 03
PTHLH Parathyroid hormone-like hormone Extracellular space Other 1.710 1.39e − 03
EMP1 Epithelial membrane protein 1 Plasma membrane Other 1.690 4.14e − 03
FAM132B Family with sequence similarity 132, member B Unknown Other 1.680 2.48e − 03
FRMD6 FERM domain containing 6 Cytoplasm Other 1.680 4.08e − 03
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 Unknown Other 1.680 6.70e − 04
KCNMA1 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 Plasma membrane ion channel 1.670 9.85e − 04
PTPN22 Protein tyrosine phosphatase, nonreceptor type 22 (lymphoid) Cytoplasm Phosphatase 1.670 1.35e − 03
RND3 Rho family GTPase 3 Cytoplasm Enzyme 1.660 1.73e − 03
BCAR3 Breast cancer antiestrogen resistance 3 Cytoplasm Other 1.650 3.80e − 03
FLI32255 Hypothetical protein Loc643977 Unknown Other 1.650 3.90e − 03
ANKRD55 Ankyrin repeat domain 55 Nucleus Transcription regulator 1.620 2.20e − 03
GADD45A Growth arrest and DNA damage–inducible, alpha Nucleus Other 1.620 2.25e − 03
PDGFA Platelet-derived growth factor alpha polypeptide Extracellular space Growth factor 1.620 9.14e − 04
CD274 CD274 molecule Plasma membrane Other 1.610 4.15e − 04
PDCD1LG2 Programmed cell death 1 ligand 2 Plasma membrane Other 1.610 3.80e − 03
F3 Coagulation factor III (thromboplastin, tissue factor) Plasma membrane Transmembrane receptor 1.600 1.74e − 03
MTHFD2 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 Cytoplasm Enzyme 1.600 7.73e − 03
DNER Delta/notch–like EGF repeat containing Plasma membrane Transmembrane receptor 1.590 1.49e − 03
CEBPG CCAAT/enhancer binding protein (C/EBP), gamma Nucleus Transcription regulator 1.580 6.97e − 03
FAM40B Family with sequence similarity 40, member B Unknown Other 1.580 9.61e − 03
PIK3CD Phosphoinositide-3-kinase, catalytic, delta polypeptide Cytoplasm Kinase 1.570 2.64e − 03
ARHGEF2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 Cytoplasm Other 1.560 5.52e − 03
STX1A Syntaxin 1A (brain) Cytoplasm Transporter 1.560 3.76e − 03
TRIB1 Tribbles homolog 1 (Drosophila) Cytoplasm Kinase 1.560 2.19e − 03
ENOX1 Ecto-NOX disulfide-thiol exchanger 1 Unknown Other 1.550 1.25e − 03
TMCC3 Transmembrane and coiled-coil domain family 3 Unknown Other 1.550 1.42e − 03
GARS Glycyl-tRNA synthetase Cytoplasm Enzyme 1.540 5.75e − 03
PIK3AP1 Phosphoinositide-3-kinase adaptor protein 1 Cytoplasm Other 1.540 3.76e − 03
USP53 Ubiquitin-specific peptidase 53 Unknown Enzyme 1.540 5.53e − 04
SLC38A1 Solute carrier family 38, member 1 Plasma membrane Transporter 1.530 3.05e − 03
DUSP4 Dual-specificity phosphatase 4 Nucleus Phosphatase 1.520 1.73e − 03
FOXQ1 Forkhead box Q1 Nucleus Transcription regulator 1.520 1.51e − 03
IL11 Interleukin 11 Extracellular space Cytokine 1.520 8.34e − 04
Table W1. (continued )
Gene Symbol Entrez Gene Name Location Type(s) Fold Change P
MYADM Myeloid-associated differentiation marker Nucleus Other 1.520 4.26e − 03
MB2 Metastasis-related protein mb2 Unknown Other 1.520 5.95e − 03
AKAP12 A kinase (PRKA) anchor protein 12 Cytoplasm Transporter 1.510 6.02e − 03
PHACTR2 Phosphatase and actin regulator 2 Unknown Other 1.510 5.86e − 03
RASA3 RAS p21 protein activator 3 Plasma membrane Other 1.510 1.01e − 04
SARS Seryl-tRNA synthetase Cytoplasm Enzyme 1.510 8.21e − 03
FOSL1 FOS-like antigen 1 Nucleus Transcription regulator 1.510 1.60e − 03
KLF6 Kruppel-like factor 6 Nucleus Transcription regulator 1.510 6.73e − 04
RGS7 Regulator of G protein signaling 7 Cytoplasm Enzyme 1.500 8.44e − 04
GEM GTP binding protein overexpressed in skeletal muscle Plasma membrane Enzyme 1.500 7.04e − 04
IRAK2 Interleukin-1 receptor–associated kinase 2 Plasma membrane Kinase 1.500 1.93e − 03
SH2D5 SH2 domain containing 5 Unknown Other 1.500 1.76e − 03
WIPF3 WAS/WASL interacting protein family, member 3 Plasma membrane Other 1.500 4.22e − 03
Summary of microarray data analysis (Gene Expression Omnibus data set GSE28167) showing messenger RNA up-regulation (>1.5 fold) in U251 glioma cells migrating on aligned versus randomly
oriented nanofibers. Genes in bold face emphases have been described in the literature as regulators or targets of JAK/STAT signaling [24–26]. Results were analyzed by BRB-Array Tools software using a
modified t test with random variance (P < .05 indicates statistically significant differences).
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Table W3. List of Primers Used for Quantitative RT-PCR.
Gene Forward Sequence 5′ → 3′ Reverse Sequence 5′ → 3′
CAMK2N1 TATTGAAGATGATAGGATTG AATTTTGACAAATAGCTGCA
CAPS AGCTGCATTTGCCAAGCTGG GCTGTAGTAGTCCTGGAATT
CCND1 GCGGRAGTAGGACAGGAAGTT GAACAAACAGATCATCCGCAAAC
CXCL2 ACTGAACTGCGCTGCCAGTG TTCTGCCCATTCTTGAGTGT
CXCL3 TCAAGAACATCCAAAGTGTG TTGTTCAGTATCTTTTCGAT
EDG1 TATGCCAGTATGCTCTGGCT CGATGAGTGATCCAGGCTTT
EDNRB ATGTGTAAGCTGGTGCCTTT TTTGGAACCCCAATTCCTTT
EMP1 ATGGAGAAGGGAAACCGGTT GATACTGCGTTCCATCACGA
IL-8 AGACATACTCCAAACCTTTC TCTGCACCCAGTTTTCCTTG
IL-11 AAATTCCCAGCTGACGGGGA AAATAAATAAGATCTGGCTTTG
KLF2 GACTTAGGGTGGTAAAGGC CATGGACAGGATGAACTCCA
MMP2 CCATCGAGACCATGCGGAAG CCTGTATGTGATCTGGTTCTTG
MMP9 TCATCCAGTTTGGTGTCGCG GACCACAACTCGTCGTCGTC
MMP13 GAGGTGACTGGCAAACTTGA ATATCAGGGGTGTAATTCAC
PARP9 AAATGTCCTGTGCCTCCAAC ACTCTGCATACCACATTGCA
PDGFA AGTGAGGATTCTTTGGACCAC TTGACACTGCTCGTGTTGCA
PDGFRA TACCAGGGAGGTCAAAGAAA TTCCTGAATCTTTTCCACAT
PI15 GATTATGCTTTTCCATATCCC ATCCTATCCGATTGGAAGTG
RND3 AATAGAGTTGAGCCTGTGGG ATCAGACTTGCAGCCGACCA
SERPINE1 TTTCAGAGGTGGAGAGAGCC AAGGGAGTCTTCCACTGGCC
SESN3 GTTCATGTCAATCTACTTTT TCATGATTTATGATCAGTAT
SOX4 TAGTTCTTGCACGCTCTTTA TTCCCTGAAGCAGTTGATTC
SOX13 AAGGAGCTCCAGCTTCTGGT AGGAGGTTGATCTTATGCTG
SOX21 AAGATGCACAACTCGGAGAT CGACGAGATCTCTGCCATTT
SPHK1 CTGGTGGTCATGTCTGGAGA CAGCAATAGCGTGCAGTTGG
STC1 TTGCATGCCTGGAAAACTCC CCGTTGGCGATGCATTTTAA
STX1A TCAAGTACCAGAGCAAGGC GCAGATGATGATCATGATTT
VANGL2 AGCGTCGCTGGATTTTCTCT ATCTCGACTCTTAGAGCGGT
Figure W2. Inhibitionof actinpolymerizationdisrupts two-dimensional
glioma cell migration. (A) Representative image of unfixed, CMFDA-
labeled U251 glioma cells migrating out of a spheroid deposited on
aligned nanofibers. (B) Same cells from A, imaged after fixation and
stainingwith phalloidin–Alexa 594 to detect actin F. The stainingwas
mostly cortical and diffuse. Bars, 100 μm. (C) Effect of cytochalasin
D (Cyt-D) on the migration of U251 cells, measured using a wound
healing assay. Cell migration was significantly inhibited at 2.0 μM
Cyt-D and completely abolished at 2 μM due in part to cell detach-
ment. *P < .05, **P < .01, ***P < .001 by two-way ANOVA for
repeated measures.
Figure W3. STAT3 inhibitors disrupt glioma cell migration. Represen-
tative images of G9 spheroids (glioblastoma-derived initiating cells)
cultured on aligned nanofibers scaffolds in the presence of increasing
concentrations of the STAT3 inhibitor stattic. Notice the reduction of
cell dispersion along the major axis of the scaffold, without a notice-
able decrease in fluorescence (ratio of integrated fluorescence/area
remained approximately constant). Bars, 200 μm.
Figure W4. STAT3 inhibitors do not disrupt cell viability at early culture times. U251 (A) and G9 (B) glioma cell were cultured on aligned
nanofiber for 24 to 72 hours in the presence of the STAT3 inhibitors stattic and LLL12. Toxicity of these compounds was measured
using an assay for metabolic reduction of tetrazolium. Results showed that neither stattic nor LLL12 reduced cell viability in the con-
ditions at which they inhibited cell migration (0.5-2 μM for up to 24 hours). Negative effects on cell viability were observed only at the
highest concentrations tested and longer incubation times (>48 hours).
Figure W5. STAT3 inhibition reduces MLC2 phosphorylation of
cells cultured on aligned nanofibers. U251 glioma cells were cul-
tured on aligned nanofibers or TCPS for 24 hours in the presence
of 1 μM stattic, collected, and processed for Western blot analysis.
Results showed that a low concentration of the STAT3 inhibitor par-
tially reduced STAT3 phosphorylation in cells of myosin II, MLC2. In
contrast, neither STAT3 nor MLC2 phosphorylation was affected by
the same treatment when cells were cultured on TCPS.
Figure W6. STAT3 inhibition reduces cell dispersion in cultured
brain slices. G9 glioma cells were treated with 1 μM stattic of
1 μM LLL12 overnight and deposited on brain slices prepared as
described in the Materials and Methods section. Dispersion of the
cells in the tissue slice was followed by fluorescence microscopy
for 96 hours. (A) Cell migration followed a pattern of dispersion
with typical trails of cells dispersing out of tumorspheres, which
was abolished by the pharmacological treatments. (B) Quantitative
results indicated that cell dispersion had been significantly re-
duced by treatment with low concentrations of the STAT3 inhibi-
tors, in agreement with the results observed using nanofiber
scaffolds. **P< .01, ***P< .001 by two-way ANOVA for repeated
measures. Bars, 200 μm.
